Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.

UiPath (PATH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Despite a 20% stock decline, we maintain a bullish view on UiPath due to its strategic pivot to Agentic AI and strong ...

Leading CISOs honored for leadership, security, and business impact SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- The 2025 ...

Learn more about whether UiPath Inc. or Qualys, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Asana, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare ...

UiPath shares rise on launch of generative AI-based UiPath Medical Record Summarization agent at Google Cloud Next 2025.

AppLovin Corporation APP and UiPath Inc. PATH are two prominent players leveraging artificial intelligence to transform digital operations. AppLovin operates in the mobile ad tech space, using AI to ...

UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced at Google Cloud Next 2025 the launch of its generative AI-based UiPath Medical Record Summarization agent, ...

UiPath (PATH) announced at Google Cloud Next 2025 the launch of its generative AI-based UiPath Medical Record Summarization agent, powered by ...

UiPath (PATH) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Founders stepping aside for outside CEOs and then returning as CEO later on is quite a trope in the tech world, and Daniel ...